

**Supplementary Table S1.** The characteristics of the MPA patients and GPA patients.

Characteristic	MPA	GPA	<i>p</i>
Case, n	306	33	
Age (years)	60.7 ± 12.9	50.4 ± 15.1	<0.001
Life survival time (months)	71.1 ± 37.3	64.2 ± 34.3	0.319
Kidney survival time (months)	49.5 ± 39.4	53.0 ± 37.2	0.639
Gender (Male/Female), n	127/179	15/16	0.567
Hypertension, n (%)	147 (48.0)	9 (27.3)	0.058
Diabetes, n (%)	23 (7.5)	3 (9.1)	0.720
Leukocyte counts (10 <sup>9</sup> /l)	7.9 ± 3.5	8.0 ± 3.1	0.880
Haemoglobin (g/l)	83.0 (73.0, 98.0)	101.0 (81.0, 116.0)	0.021
Platelets counts (10 <sup>9</sup> /l)	224.3 ± 95.0	242.7 ± 98.1	0.315
Daily urine protein (g)	1.8 (0.8, 3.1)	1.0 (0.3, 1.7)	<0.001
Urine red cell counts (n/μl)	189.7 (66.6, 606.3)	265.0 (50.4, 801.4)	0.368
Albumin (g/l)	32.8 ± 5.6	32.7 ± 6.4	0.909
Globulin (g/l)	30.9 ± 6.1	30.2 ± 5.7	0.531
Creatinine (μmol/l)	282.0 (127.5, 506.5)	141.0 (75.0, 360.0)	0.129
EPI-GFR (ml/min/1.73m <sup>2</sup> )	16.9 (8.0, 40.5)	40.6 (11.8, 90.4)	0.007
ESR (mm/h)	70.1 ± 37.5	65.3 ± 44.4	0.535
CRP (mg/l)	15.5 (4.0, 60.2)	30.2 (2.9, 72.4)	0.072
MPO, (RU/mL)	58.5 (27.5, 100)	0.9 (0.5, 1.6)	<0.001
PR3 (RU/mL)	1.4 (1.0, 2.0)	62.0 (16.3, 100.0)	<0.001
BVAS	15.0 (12.0, 18.0)	14.0 (10.5, 19.0)	0.314
<i>Treatment</i>			
Prednisone only/combined immunosuppressants, n	99/180	15/12	0.059
Intravenous cyclophosphamide/ mycophenolate mofetil, n	90/90	9/3	0.136
Methylprednisolone impulses, n	112	10	1.000
<i>Outcome</i>			
Relapse, n (%)	52 (17.0)	8 (24.2)	0.222
Maintaining dialysis, n (%)	126 (41.2)	9 (27.3)	0.249
Death, n (%)	90 (29.4)	9 (27.3)	1.000

eGFR: estimated glomerular filtration rate calculated by EPI formula; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; MPO: anti-myeloperoxidase; PR3: anti-proteinase 3; BVAS: Birmingham Vasculitis Activity Score; Combined immunosuppressants: patients treated by prednisone combined with intravenous cyclophosphamide or mycophenolate mofetil.